The Life Sciences Report: You have said that the pharma drug discovery model is broken, and have written about this extensively. Would you describe your thesis?
Mark Kessel: The number of new chemical entities that have come out of big pharma’s research and development (R&D) pipeline has been anemic in recent years. There are a number of reasons for this. One is the bureaucracy that has resulted from the growth of these companies and the number of people who have to sign off on various projects, which has tended to stifle innovation. Big pharma has resorted to various models … [visit site to read more]
- Out of the Red and into the Black: John McCamant on Investment in Blood Cancer Companies The Life Sciences Report: I know you have great interest...
- Reap Biotech Profits from Overlooked Spaces: Alan Carr The Life Sciences Report: Alan, what is your current theme?...
- Being Selective in Biotech: Carol Werther The Life Sciences Report: Biotech stocks began the year with...
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here